Intra-Cellular Therapies Inc
Suletud
SektorTervishoid
0
Ülevaade
Aktsiahinna muutus
24h
Min
Max
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | -0.79% downside |
Uudiste sentiment
By Acuity
50%
50%
155 / 345 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Weak Bullish Evidence
Intra-Cellular Therapies Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Intra-Cellular Therapies Inc Prognoos
Hinnasiht
By TipRanks
-0.79% langus
12 kuu keskmine prognoos
Keskmine 130.83 USD -0.79%
Kõrge 132 USD
Madal 118 USD
Põhineb 13 Wall Streeti analüütiku instrumendi Intra-Cellular Therapies Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
155 / 345 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
